Feb 5 (Reuters) - Zenas Biopharma Inc ZBIO.O:
ZENAS BIOPHARMA : TOPLINE RESULTS FROM PHASE 2 TRIAL IN RELAPSING MULTIPLE SCLEROSIS (MOONSTONE) EXPECTED IN Q3 2025
ZENAS BIOPHARMA :TOPLINE RESULTS FROM PIVOTAL PHASE 3 TRIAL IN IMMUNOGLOBULIN G4-RELATED DISEASE (INDIGO) EXPECTED YEAR-END 2025
Source text: ID:nGNX3GBN3c
Further company coverage: ZBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.